NCT04775901

Brief Summary

This is a prospective, randomized, controlled study to evaluate the diagnostic yield and safety of three-dimensionally printed navigational template in percutaneous transthoracic lung biopsy.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
150

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Nov 2020

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 25, 2020

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

February 23, 2021

Completed
6 days until next milestone

First Posted

Study publicly available on registry

March 1, 2021

Completed
1.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2022

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2023

Completed
Last Updated

March 1, 2021

Status Verified

February 1, 2021

Enrollment Period

2.1 years

First QC Date

February 23, 2021

Last Update Submit

February 26, 2021

Conditions

Keywords

Biopsy, NeedlePrinting, Three-DimensionalImage-Guided Biopsy

Outcome Measures

Primary Outcomes (1)

  • Diagnostic yield of percutaneous transthoracic fine-needle aspiration

    A percutaneous transthoracic fine-needle aspiration procedure was considered diagnostic if a malignant or specific benign diagnosis of the lesion was made. The ratio of diagnostic cases to all the participants who received the corresponding biopsy was considered as diagnostic yield.

    Three to four working days post-biopsy were needed to establish the diagnosis of the cytological specimens acquired by fine-needle aspiration.

Secondary Outcomes (4)

  • Diagnostic sensitivity of percutaneous transthoracic fine-needle aspiration

    If an eventual diagnosis was attained by means of follow-up, a 12-month assessment was needed.

  • Procedural duration

    15 mins post biopsy

  • Radiation exposure

    15 mins post biopsy

  • Complication rate

    Real-time complication post biopsy indicates those recognized by the immediate CT scan, while delayed complication indicates those recognized by radiograph taken 4-6 hours post biopsy.

Study Arms (2)

CT-guided lung biopsy

OTHER

Participants in this arm received conventional CT-guided percutaneous transthoracic lung biopsy.

Other: CT-guided lung biopsy

Template-guided lung biopsy

EXPERIMENTAL

Three-dimensionally printed navigational template was designed based on the CT scan images acquired before the biopsy. Under the guidance of navigational template, percutaneous transthoracic lung biopsy was conducted.

Device: Template-guided lung biopsy

Interventions

Percutaneous transthoracic lung biopsy was conducted stepwise under the real-time guidance of CT scan. This kind of modality served as an effective method for diagnosing peripheral lung lesions (all of the participants received fine-needle aspiration, some of them received coaxial needle biopsy as well, according to the pulmonologist's instruction).

CT-guided lung biopsy

A three-dimensional model consisting of participant's thoracic image information was initially reconstructed based on the CT scan data. Afterwards, a navigational template was customized, which accommodated well to the anatomical landmarks of the participant. The template was then printed by means of stereolithography from photopolymer material. Participants would receive navigational template-guided percutaneous transthoracic lung biopsy (all of the participants received fine-needle aspiration, some of them received coaxial needle biopsy as well, according to the pulmonologist's instruction).

Template-guided lung biopsy

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • A. CT confirmed peripheral lung lesion;
  • B. Nodule size larger than or equal to 30 mm;
  • C. Scheduled for percutaneous transthoracic fine-needle aspiration;
  • D. Percutaneous transthoracic lung biopsy was conducted at supine or partially lateral decubitus;
  • E. Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2;
  • F. Written informed consent provided.

You may not qualify if:

  • A. Biopsy needle insertion route impeded by skeletal structures;
  • B. Lesion within 3 cm above diaphragmatic dome;
  • C. Insertion route longer than the biopsy needle;
  • D. Lung biopsy needed to be conducted at vertically lateral decubitus;
  • E. Any contraindication of percutaneous transthoracic lung biopsy;
  • F. Women who are pregnant or in the period of breastfeeding.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Shanghai Pulmonary Hospital

Shanghai, Shanghai Municipality, 200433, China

RECRUITING

Related Publications (2)

  • Zhang L, Li M, Li Z, Kedeer X, Wang L, Fan Z, Chen C. Three-dimensional printing of navigational template in localization of pulmonary nodule: A pilot study. J Thorac Cardiovasc Surg. 2017 Dec;154(6):2113-2119.e7. doi: 10.1016/j.jtcvs.2017.08.065. Epub 2017 Sep 1.

    PMID: 29017792BACKGROUND
  • Zhang L, Wang L, Kadeer X, Zeyao L, Sun X, Sun W, She Y, Xie D, Li M, Zou L, Rocco G, Yang P, Chen C, Liu CC, Petersen RH, Ng CSH, Parrish S, Zhang YS, Giordano R, di Tommaso L; AME Thoracic Surgery Collaborative Group. Accuracy of a 3-Dimensionally Printed Navigational Template for Localizing Small Pulmonary Nodules: A Noninferiority Randomized Clinical Trial. JAMA Surg. 2019 Apr 1;154(4):295-303. doi: 10.1001/jamasurg.2018.4872.

    PMID: 30586136BACKGROUND

MeSH Terms

Conditions

Lung Neoplasms

Condition Hierarchy (Ancestors)

Respiratory Tract NeoplasmsThoracic NeoplasmsNeoplasms by SiteNeoplasmsLung DiseasesRespiratory Tract Diseases

Study Officials

  • Chang Chen, MD, PhD

    Shanghai Pulmonary Hospital, Tongji University School of Medicine

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Prof. Dr.

Study Record Dates

First Submitted

February 23, 2021

First Posted

March 1, 2021

Study Start

November 25, 2020

Primary Completion

December 31, 2022

Study Completion

December 31, 2023

Last Updated

March 1, 2021

Record last verified: 2021-02

Data Sharing

IPD Sharing
Will not share

Locations